Bain Capital, Mitsubishi Tanabe Pharma

Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.
M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion
Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes and cancer with
Bain Capital buys Japanese pharma for $3.3B
Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to “accelerate the development and approval of innovative medicines in the Japanese market.
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
TOKYO : Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion ...
Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain to Acquire Mitsubishi Tanabe Pharma in $3.3 Billion Deal
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group Corp.’s pharmaceutical unit, adding to a dealmaking boom in Japan.
Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
Bain Capital to buy Mitsubishi Chemical’s pharma unit for $3.3B
Investment firm Bain Capital said on Friday that it has signed an agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group (OTCPK:MTLHY) for approximately 510 billion JPY (3.3 billion USD).
MedCity News4d
Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma
Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...
Bain Capital proposes to take Surgery Partners private
Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...
Business Times3d
Bain to acquire Mitsubishi Tanabe Pharma in US$3.3 billion deal
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about 510 ...
Morningstar4d
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Bain Capital ...
Business Wire5d
Bain Capital Announces Majority Investment in Milacron, a Leading Global Provider of Highly Engineered Plastic Processing Solutions
BOSTON & BATESVILLE, Ind.--(BUSINESS WIRE)--Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the ...